NUFORMIX TECHNOLOGIES LIMITED

• ⚠

  Material uncertainty over going concern

  These circumstances indicate the existence of an inherent material uncertainty which may cast a significant doubt on the Group's and Parent Company's ability to continue as a going concern.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  +211.5%

  £18,400 → £57,311

• Net assets

  -7.4%

  -£3,537,098 → -£3,797,551

• Employees

  0%

  3 → 3

• Operating profit

  -7.3%

  -£250,268 → -£268,436

• Profit before tax

  -7.3%

  -£250,268 → -£268,436

• Wages

  0%

  £90,000 → £90,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. NUFORMIX TECHNOLOGIES LIMITED 2017-10-13 → present
2. NUFORMIX LIMITED 2007-12-10 → 2017-10-13
3. SANDCO 1049 LIMITED 2007-10-23 → 2007-12-10

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

Kreston Reeves Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“These circumstances indicate the existence of an inherent material uncertainty which may cast a significant doubt on the Group's and Parent Company's ability to continue as a going concern.”

Significant events

• “On 29 May 2025, The Group announced that the European Medicines Agency ("EMA") had granted ODD in IPF for tranilast to the Group.”
• “On 11 August 2025 the Group announced that it had submitted an application to the US Food and Drug Administration ("FDA") for ODD in IPF for tranilast.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.